An 8-week, rater-blinded, real-world observational study to investigate the benefits of pharmacogenetics-based pharmacotherapy in patients suffering from schizophrenia.
Suffer from schizophrenia (as assessed in agreement with ICD-11 criteria).
Age between ≥18 and <65 years.
Currently receiving inpatient or outpatient psychiatric treatment.
Standard antipsychotic treatment for more than 2 weeks with the occurrence of drug-induced adverse effects requiring dose adjustment or a switch of medication.
Presence of organic brain disease or a severe and/or unstable physical condition.
Substance abuse or dependence within the past 6 months or currently.
Presence of elevated levels of agitation, impulsivity, or risk of self-injury or suicide.
Pregnant or breastfeeding women.